منابع مشابه
Treatment of Recurrent or Metastatic Uterine Adenosarcoma
Purpose This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy. Methods 78 patients with recurrent or metastatic adenosarcoma comprised the study population. The Kaplan-Meier ...
متن کاملManagement of recurrent or metastatic retroperitoneal soft-tissue sarcomas.
UNLABELLED Retroperitoneal soft tissue sarcomas remain a serious therapeutic problem. The aim of the study is to define the optimal treatment strategy of patients with locally recurrent or metastatic retroperitoneal soft tissue sarcomas. MATERIAL AND METHODS A retrospective study was performed.Between 2001 and 2013, 89 patients with retroperitoneal soft tissue sarcomas were surgically treated...
متن کاملTargeted Therapy in Recurrent or Metastatic Head and Neck Carcinoma
Submit Manuscript | http://medcraveonline.com Abbreviations: R/M: Recurrent and/or Metastatic; HNSSC: Head and Neck Squamous Cell Carcinoma; FU: Fluorouracil; PFS: Progression-Free Survival; OS: Overall Survival; EGFR: Epidermal Growth Factor Receptor; TGF-α: Transforming Growth Factor-Alpha; TKI: Tyrosine Kinase Inhibitors; mAb: Monoclonal Antibodies; ACU: Area Under the Concentration; PD 1: P...
متن کاملSystemic therapy for recurrent or metastatic salivary gland malignancies
Salivary gland carcinomas are notoriously resistant to therapy and no standard of care exists. Due to the rarity of these malignancies, various histologies, and wide ranging clinical behavior it has been difficult to standardize systemic therapy. We have reviewed clinical prospective studies in the last 15 years with salivary gland malignancies involving cytotoxic chemotherapy and biologic agen...
متن کاملIrinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
The 1-year survival for patients with metastatic non-small-cell lung cancer is only around 35%. We are evaluating the combination of irinotecan (Camptosar) and carboplatin (Paraplatin) in patients with stage IIIB and IV non-small-cell lung cancer. The first five patients received irinotecan, 250 mg/m2 over 90 minutes followed by carboplatin at an area under the concentration-time curve of 5 ove...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2017
ISSN: 0923-7534
DOI: 10.1093/annonc/mdx598